Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 1;25(2):513-519.
doi: 10.31557/APJCP.2024.25.2.513.

Role of CD44 and CD24 Expression on 2-years Disease Free Survival in Patients with Advanced Epithelial Ovarian Carcinoma

Yuri Feharsal  1 , Andri Andrijono  2 , Chamim Shobari Singoprawiro  1 , Lisnawati Lisnawati  3 , Trevino Aristarkus Pakasi  4 , Andi Darma Putra  2 , Fitriyadi- Kusuma  2 , Tricia Dewi Anggraeni  2 , Erlina Erlina  5 , Sarwanti Sarwanti  5 , Tha'atam Mardhiyah  2
Affiliations

Role of CD44 and CD24 Expression on 2-years Disease Free Survival in Patients with Advanced Epithelial Ovarian Carcinoma

Yuri Feharsal et al. Asian Pac J Cancer Prev. .

Abstract

Objective: Ovarian cancer is one of the most common cancers with a high mortality rate worldwide. Despite optimal surgical therapy and chemotherapy, recurrence is still common. Cancer stem cells expressing CD44 and CD24 are thought to be contributing factors in recurrence.

Methods: A cohort retrospective study with survival analysis was carried out on advanced ovarian cancer patients who underwent optimal debulking surgery followed by 6 cycles of chemotherapy at Cipto Mangunkusumo General Hospital and Fatmawati General Hospital from January 2019 to March 2023. Immunohistochemical examination was performed on tumor tissue with CD44 and CD24 expression were assessed using the H-Score method then determined the cut off-point expression level using the ROC curve. Furthermore, the relationship between these expression levels with the disease-free survival was assessed using the survival curve.

Results: There were 48 subjects who were included in the study. There were high expression levels of CD44 in 47.9% and CD24 in 50% of cases. High CD44 expression had mean and median survival of 13.2 ± 1.8 and 11 months (HR 5.05, 95% CI 1.84- 13.85). High CD24 expression had mean and median survival of 13.5 ± 2.4 and 7 months (HR 7.73, 95% CI 2.58 - 23.15). The combination of the two high expressions had mean and median survival of 10.44 ± 1.88 and 7 months.

Conclusion: High expression of CD44 and CD24 will shorten the disease-free survival of patients with advanced ovarian cancer.

Keywords: CD24; CD44; Cancer stem cells; Ovarian Cancer; disease-free survival.

PubMed Disclaimer

Conflict of interest statement

None of the authors have any conflict of interest associated with this study.

Figures

Figure 1
Figure 1
Degree of Immunohistochemical Stain Intensity of CD44 Expression, Positive in Cell Membrane. (A) High staining, (B) Moderate staining, (C) Low staining, and (D) None
Figure 2
Figure 2
Degree of Immunohistochemical Stain Intensity of CD24 Expression, Positive in Cell Membrane. (A) High staining, (B) Moderate staining, (C) Low staining, and (D) None
Figure 3
Figure 3
ROC Curve of CD44 and CD24 H-Score
Figure 4
Figure 4
Kaplan-Meier Curve of CD44 Expression Against Disease-Free Survival
Figure 5
Figure 5
Kaplan-Meier Curve of CD24 Expression Against Disease-Free Survival
Figure 6
Figure 6
. Kaplan-Meier Curve of The CD44 and CD24 Combination in Relation to Disease-Free Survival
See this image and copyright information in PMC

References

    1. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: A review. Cancer Biol Med. 2017;14(1):9–32. - PMC - PubMed
    1. GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide in 2020 of WebLog [Online] [Accessed 24 July; 2021]. Available from: https://gco.Iarc.Fr/today/data/factsheets/populations/900-world-fact-she....
    1. INASGO. Prevalensi kanker ovarium of WebLog [Online] [Accessed 24 July; 2021]. Available from: http://www.Inasgo.Org/map.Asp.
    1. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: Epidemiology and risk factors. Int J Womens Health. 2019;11:287–99. - PMC - PubMed
    1. Kurta ML, Edwards RP, Moysich KB, McDonough K, Bertolet M, Weissfeld JL, et al. Prognosis and conditional disease-free survival among patients with ovarian cancer. J Clin Oncol. 2014;32(36):4102–12. - PMC - PubMed